[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560802":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University College, London","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort",null,"* Social Responsiveness Scale (SRS - II)\n* ADHD Rating scale (5th edition) (ADHD - RS V)\n* Child Behaviour Checklist (CBCL)\n* Revised Children's Anxiety and Depression Scale (RCADS-P)\n* Behaviour Rating Inventory of Executive Function (BRIEF - P)\n* Wechsler Intelligence test for children version V (WISC-V)\n* Autism Diagnostic Observation Schedule (ADOS)\n* Behavioural Assessment of the Dysexecutive Syndrome for Children (BADS-C)\n* Psychophysiological task: A task previously used to measure the emotional response of patients through the usage of visual and auditory aversive stimuli. The emotional response will be measured through skin conductance, heartrate, pupil responses.\n* Purdue Pegboard\n* A subset of patients will be also asked to undergo an MRI brain scan",[13],"Behavioral: Classical conditioning task",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BEHAVIORAL","Classical conditioning task","To evaluate the neurophysiological and physiological response to a classical conditioning task, which is comparable to findings that have been made in the mdx dystrophic mouse (deficient in Dp427). The investigators will assess correlations between the specific DMD\u002FBMD genotype and susceptibility to conditioning, as well as the relationship between conditioning and behavioural\u002Femotional characteristics of the syndrome.",[9],[21],{"name":22,"affiliation":5,"role":23},"Francesco Muntoni, Professor","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Anna Kolesnik, Dr","CONTACT","44 (0) 20 7905 2600","braindmd@ucl.ac.uk",{"name":31,"role":27,"phone":28,"phoneExt":10,"email":32},"Natasha Aslam, MSc","natasha.aslam@ucl.ac.uk",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UCL GOS Institute of Child Health","RECRUITING","London","WC1N 1EH","United Kingdom","UK",{"type":42,"coordinates":43},"Point",[44,45],-0.12574,51.50853,{"lat":45,"lon":44},[48,50,51,52],{"name":49,"role":27,"phone":10,"phoneExt":10,"email":29},"Anna Kolesnik, PhD",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},{"name":22,"role":27,"phone":10,"phoneExt":10,"email":10},{"name":53,"role":27,"phone":10,"phoneExt":10,"email":10},"David Skuse, Professor",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[57],{"name":58,"class":59},"Sarepta Therapeutics, Inc.","INDUSTRY","100560802","defining-outcome-measures-for-behavioural-and-emotional-problems-in-dystrophinopathies-100560802",false,"NCT06581887","Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies","D-BRAIN","Inclusion Criteria:\n\n* DMD patients:\n\n  1. Male\n  2. Age range 7-17 years\n  3. A genetically proven diagnosis of DMD.\n  4. A genetic mutation that abrogates expression of Dp427 alone (assigned in DMD Group 1: Dp427-\u002FDp140+) or both Dp427 and Dp140 (assigned to DMD Group 2: Dp427-\u002FDp140-).\n  5. Ability to consent\u002Fassent\n\nBMD patients:\n\n1. Male\n2. Age range 7-17 years\n3. A genetically proven diagnosis of BMD.\n4. A genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1), of both Dp427 and Dp140 (assigned to BMD Group 2).\n5. Ability to consent\u002Fassent\n\nControl participants:\n\n1. Male\n2. Age range 7-17 years.\n3. Ability to consent\u002Fassent\n\nExclusion Criteria:\n\n* DMD \\& BMD patients:\n\n  1. Significant visual or hearing impairment\n  2. Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study\n  3. Current participation in a clinical trial investigating a new drug involved in dystrophin modulation.\n  4. Inability to consent (for parents\u002Fguardians or self-reporting participants aged 16 and 17) or assent. This will exclude the rare individuals with extremely severe learning disability, as the assent in these patients is impossible (or the consent in self-reporting participants aged 16 and 17).\n\nControl participants:\n\n1. Significant visual or hearing impairment\n2. Specific phobias or sensory sensitivities to stimuli similar to the ones used in this study\n3. Any diagnosis of neurological or psychiatric condition\n\nGeneral exclusion criteria for MRI:\n\n1. Claustrophobia\n2. Pacemakers and defibrillators\n3. Nerve stimulators\n4. Intracranial clips\n5. Intraorbital or intraocular metallic fragments\n6. Cochlear implants\n7. Ferromagnetic implants (e.g. thoracic implant for scoliosis)\n8. Inability to lie supine during less than 45 minutes\n9. Not having a general practitioner\n10. Severe learning disability which will require a general anaesthetic",true,"MALE","7 Years","17 Years",{"count":72,"type":73},100,"ESTIMATED","OBSERVATIONAL","Study aims to develop and to evaluate the neurophysiological and physiological response to a classical conditioning task.To better understand how Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) impacts mental health and how to assess it. Participants invited to complete questionnaires about behaviour, cognitive function and social interactions, complete computer tasks and have an optional MRI brain scan,",[77,78],"DMD","BMD",[80],"Antisense oligonucleotide","2024-08-29",{"date":83,"type":84},"2024-09-03","ACTUAL",{"date":86,"type":84},"2022-09-13",{"date":88,"type":73},"2024-12-31",{"name":5,"class":6},1]